Valneva (VALN)

• Market cap: $355M
• 1 day: 1.39%
• 5 days: -2.02%
• 1 month: 18.43%
• 3 months: -22.24%
• 6 months: -43.54%
• Year to date: -7.42%
• 1 year: -51.82%
• 5 years: -84.59%
• 10 years: -84.59%

About: Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Employees: 676

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.03% less ownership

Funds ownership: 0.47% [Q2] → 0.44% (-0.03%) [Q3]

8% less capital invested

Capital invested by funds: $4.75M [Q2] → $4.35M (-$392K) [Q3]

9% less funds holding

Funds holding: 11 [Q2] → 10 (-1) [Q3]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2